Nasdaq GlobeNewswire

Constellation Brands to Present at Consumer Analyst Group of New York Conference, February 21, 2018

Del

VICTOR, N.Y., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today that Bill Newlands, president and chief operating officer, and David Klein, chief financial officer, will present at the Consumer Analyst Group of New York (CAGNY) conference on Wednesday, February 21, 2018, at the Boca Raton Resort & Club in Florida. The presentation is scheduled to begin at 3:00 p.m. EST and is expected to cover the company's strategic business activities, financial and operational performance, and outlook for the future.

A live audio webcast of the presentation can be accessed on the company's website at www.cbrands.com by following the instructions in the "Investors" section. Following the presentation, the webcast will be available on the company's website for replay through the close of business on Wednesday, March 28, 2018. Financial and statistical information discussed in the presentation and a reconciliation of any reported (GAAP) financial measures with comparable or non-GAAP financial measures will also be available on the company's website in the "Investors" section under "Financial History."

About Constellation Brands
Constellation Brands (NYSE:STZ) (NYSE:STZ.B), a Fortune 500® company, is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported brands such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. The company's beer portfolio also includes Ballast Point, one of the most awarded craft brewers in the U.S. In addition, Constellation is the world leader in premium wine, selling great brands that people love, including Robert Mondavi, Clos du Bois, Kim Crawford, Meiomi, Mark West, Franciscan Estate, Ruffino and The Prisoner. The company's premium spirits brands include SVEDKA Vodka, Casa Noble Tequila and High West Whiskey.

Based in Victor, N.Y., the company believes that industry leadership involves a commitment to brand building, our trade partners, the environment, our investors and to consumers around the world who choose our products when celebrating big moments or enjoying quiet ones. Founded in 1945, Constellation has grown to become a significant player in the beverage alcohol industry with more than 100 brands in its portfolio; about 40 wineries, breweries and distilleries; and approximately 10,000 talented employees. We express our company vision: to elevate life with every glass raised. To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

Media Contacts: 
Mike McGrew: 773-251-4934
Amy Martin: 585-678-7141
Investor Relations Contacts: 
Patty Yahn-Urlaub: 585-678-7483
Bob Czudak: 585-678-7170

An attachment accompanying this release is available at http://resource.globenewswire.com/Resource/Download/f721e759-816e-4d8b-882f-681c1973b1cc




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Constellation Brands, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Feelunique–Europe’s largest online beauty retailer–expands partnership with Moovweb13.12.2018 03:28Pressemelding

Feelunique will introduce a new App-like Mobile Site powered by Moovweb SAN FRANCISCO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Feelunique, Europe’s largest online beauty retailer, announced today that it has expanded its long-standing partnership with Moovweb, by building an innovative Progressive Web App (PWA) with The Moovweb Experience Delivery Network (XDN) that powers modern mobile experiences for the world’s leading brands. The company’s new eCommerce experience will allow shoppers to browse, checkout and purchase items as fast as an app in their mobile browser without requiring a mobile app download. Powered by The Moovweb XDN, the new web experience will dramatically speed up mobile shopping–search, browsing and buying products–leveraging PWA technology. Now that page load speed is a key factor for SEO thanks to new rules that rank which mobile sites appear first on Google, best-in-class eCommerce brands are utilizing PWA technology. With PWAs, follow-up pages are pre-cached giving t

Chvaletice Manganese Project Mineral Resource Update, 2018 Metallurgical Testwork Program Update and Preliminary 2019 Plans13.12.2018 03:03Pressemelding

HIGHLIGHTS: Successful 2018 Drilling Program results in updated Mineral Resource Estimate with 98.3% of Resource classified in Measured Category. Drilling Program confirmed outstanding consistency of manganese grade and mineralogy. Successful Metallurgical Testwork Program and Pilot Plant Test runs, indicating manganese can be extracted from Chvaletice tailings using a combination of proven commercial technologies. Testwork Program confirmed the proposed hydrometallurgical process can produce Ultra-High-Purity Manganese Products meeting or exceeding customer specifications. Plan to build and commission a Demonstration Plant in 2019 to produce multi-tonne, Ultra-High-Purity Manganese Product samples for customer testing and qualification. Project timeline remains on track, with Preliminary Economic Assessment targeted for release in early 2019. Targeting production of both electrolytic manganese metal and manganese sulphate monohydrate, focusing principally on Europe's rapidly emerging

Quantenna and Telefónica Reinforce Strategic Partnership with New Portfolio of 8x8 MIMO Wi-Fi 6 Products12.12.2018 23:00Pressemelding

SAN JOSE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ: QTNA) is further strengthening its strategic partnership with Telefónica. Through a long history of cooperation, the two companies have developed multiple generations of best-in-class products including gateways, repeaters and set-top boxes deployed in Europe and Latin America. Leveraging Quantenna’s 8x8 QSR10GU-AX, Telefónica is delivering a new portfolio of high-end fiber gateways and repeaters. The Wi-Fi 6 compliant QSR10GU-AX provides integrated dual-band, dual-concurrent 2.4GHz and 5GHz functionality in the same chipset, supporting up to a maximum speed of 10Gbps and 12 simultaneous streams. Thanks to its “Always-On DFS” feature, the QSR10GU-AX offers enhanced radar detection and spectrum analyzer capabilities with wide frequency range analysis. The QSR10GU-AX also supports advanced MU-MIMO, allowing for transmission to multiple devices at the same time, and providing higher throughput, inc

Improved Accuracy and Speed for Disease Research, Two Genomic Companies Integrate Kits and Software to Enable Deep Exploration of Epigenetic Data12.12.2018 21:16Pressemelding

OnRamp’s ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamics track plots and advanced collaboration capabilities SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- OnRamp BioInformatics, a genomics company focused on scientist-friendly bioinformatics software solutions, today announced they are working with Active Motif to improve accuracies in data analysis for ChIP-Seq experiments. OnRamp’s flagship software, ROSALIND, provides a point-and-click experience to speed up and simplify the process of genomic data analysis from experiment setup to QC and interactive data visualization to interpretation. With this integration, researchers will now benefit from an optimized analysis that includes the unique characteristics of Active Motif kits and antibodies, including Unique Molecular Identifiers (UMI) and spike-in solutions. Active Motif customers will now be able to rapidly interpret their data with ROSALIND’s identificati

Markforged launches H13 tool steel for high-strength, high-temp tooling applications12.12.2018 15:00Pressemelding

New material for Metal X 3D printing system is first of many WATERTOWN, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Markforged, the Boston-area 3D printer company transforming manufacturing, today announced the launch of H13 tool steel for the Metal X, the world’s leading desktop-sized metal printer with over 150 systems shipped since March 2018. The expansion into H13 will enable customers to print parts in high-strength, high-temperature applications such as metal forming tools, dies and punches, and hardened inserts for fixtures, and even injection molds with conformal cooling channels. To learn more about H13 tool steel and place an order, please visit http://markforged.com/h13 “We designed the Metal X system to change the way things are made, and the launch of H13 is the next step down that path,” said Jon Reilly, Markforged VP of product. “For manufacturers of high-volume plastic parts this is a game changer, significantly accelerating the speed at which they can bring new products

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease12.12.2018 14:30Pressemelding

Bermekimab Therapy Rapidly and Significantly Reduces Disease AUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints. Thirty eight patients in two treatment groups received a low (n=10) or high (n=28) dose of bermekimab once weekly for either a 4 or 7-week treatment regimen, respectively. Statistically significant improvement was seen for all efficacy endpoints in the high dose group; and a significant dose response for the high dose compared to low dose group was observed for key endpoints, including the Eczema Area and Severity Index (EASI), Global Individual Sign Score (GISS), Patient Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), and SCORing Atopic Dermatitis (SCORAD). While clinically and statistically significant

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom